Logo 1 Logo 2

Clinical Trial Details

Trial ID: L5983
Source ID: NCT05103306
Associated Drug: Empagliflozin 25 Mg
Title: Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
Acronym: LUCID
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Empagliflozin 25 MG|DRUG: INS
Outcome Measures: Primary: Changes in HbA1c From Baseline to months 36, Changes in HbA1c From Baseline to months 36 (3-year), Baseline, month 36 (3-year) | Secondary: Achievement of target HbA1c, Percentage of Patients Who Achieved Glycemic Target of HbA1c at month 36, Baseline, month 36|Changes in HbA1c, Changes in HbA1c From Baseline to each time frame, Baseline, month 3, 6, 12, 18, 24, 30|Changes in FPG, Changes in fasting plasma glucose level from baseline to each month, Baseline, month 3, 6, 12, 18, 24, 30, 36|Changes in lipid profiles, Changes in total cholesterol, triglyceride, HDL-cholesterol and LDL cholesterol from baseline to month 36, Baseline, month 36|Changes in body weight, Changes in body weight from baseline to month 36, Baseline, month 36|Changes in blood pressure, Changes in systolic and diastolic blood pressure from baseline to month 36, Baseline, month 36|Percentage of patients with hypoglycemic episodes, All episodes consistent with hypoglycemia with or without a confirmatory blood glucose reading were collected., Baseline, month 36|Percentage of patients with at least 1 episode of genitourinary tract infections, Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections, Baseline, month 36
Sponsor/Collaborators: Sponsor: Chungbuk National University Hospital
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases:
Enrollment: 300
Study Type: OBSERVATIONAL
Study Designs: Observational Model: |Time Perspective: p
Start Date: 2017-01
Completion Date: 2022-12
Results First Posted:
Last Update Posted: 2022-07-20
Locations:
URL: https://clinicaltrials.gov/show/NCT05103306